DelveInsight’s, “Protein-Tyrosine-Phosphatase Inhibitors – Pipeline Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Protein-Tyrosine-Phosphatase Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Protein-Tyrosine-Phosphatase Inhibitors: Overview
Protein tyrosine phosphatases, or PTPs, are type I transmembrane proteins, membrane associated proteins or proteins localized in nuclei. Biochemicals that inhibit PTP have many applications in biochemical and physiological research. Protein tyrosine phosphatases (PTPs) play crucial roles in signal transduction and their functional alteration has been detected in many diseases. PTP inhibitors have been developed as therapeutic drugs for diseases that are related to the activity of PTPs. rotein tyrosine phosphorylation is regulated by balanced action of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs) in mammalian cells. There are over 100 PTPs encoded in the human genome sharing a short active site ‘signature motif’. Based on the amino acid sequences of their catalytic domains, PTPs are divided into four main families: (i) class I cysteine-based PTPs, (ii) class II cysteine-based PTPs: tyrosine-specific low molecular weight phosphatases, (iii) class III cysteine-based PTPs: Cdc25 phosphatase family, and (iv) aspartic acid-based PTPs. Even though PTP inhibitors are difficult to develop, lifting the fog of phosphatase inhibition is of the great market potential and further clinical impact.
"Protein-Tyrosine-Phosphatase Inhibitors - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Protein-Tyrosine-Phosphatase Inhibitors pipeline landscape is provided which includes the disease overview and Protein-Tyrosine-Phosphatase Inhibitors treatment guidelines. The assessment part of the report embraces, in depth Protein-Tyrosine-Phosphatase Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Protein-Tyrosine-Phosphatase Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Protein-Tyrosine-Phosphatase Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Protein-Tyrosine-Phosphatase Inhibitors.
This segment of the Protein-Tyrosine-Phosphatase Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Protein-Tyrosine-Phosphatase Inhibitors Emerging Drugs
JAB-3068: Jacobio Pharmaceuticals
JAB-3068 is a novel protein tyrosine phosphatase inhibitor (PTPi) with independent intellectual property rights. To date, three pharmaceutical companies worldwide are engaged in the Phase I clinical studies with anti-cancer agent in this field. JAB-3068 functions through both target therapy and immuno-oncology mechanisms. As an oral monotherapy, it has demonstrated significant anti-tumor activity; it can also promote the tumor-inhibitory immune function, offering opportunities to be combined with PD1 antibody and other drugs. In May 2020, the company entered into a license and collaboration agreement with AbbVie in relation to, amongst others, the research, development and commercialization of certain SHP2 inhibitors including JAB-3068 and JAB-3312 in May.
ERAS-601: Erasca
ERAS-601, a potential best-in-class inhibitor of the Src homology region 2 domain-containing phosphatase-2 (SHP2), was licensed from NiKang Therapeutics, Inc. SHP2 also drives tumor cell proliferation and development of resistance. SHP2 inhibitor is designed to block oncogenic signal transduction and delay the onset of resistance, thereby potentially serving as a backbone of combination therapy. It is currently being evaluated in Phase I stage of development for the treatment of solid tumors.
Further product details are provided in the report……..
This segment of the report provides insights about the different Protein-Tyrosine-Phosphatase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 20+ key companies which are developing the therapies for Protein-Tyrosine-Phosphatase Inhibitors. The companies which have their Protein-Tyrosine-Phosphatase Inhibitors drug candidates in the most advanced stage, i.e. phase II include Jacobio Pharmaceuticals.
DelveInsight’s report covers around 20+ products under different phases of clinical development like
Protein-Tyrosine-Phosphatase Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Protein-Tyrosine-Phosphatase Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Protein-Tyrosine-Phosphatase Inhibitors drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Protein-Tyrosine-Phosphatase Inhibitors: Overview
Pipeline Therapeutics
Therapeutic Assessment
Mid Stage Products (Phase II)
JAB-3068: Jacobio Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ERAS-601: Erasca
Drug profiles in the detailed report…..
Inactive Products
Protein-Tyrosine-Phosphatase Inhibitors Key Companies
Protein-Tyrosine-Phosphatase Inhibitors Key Products
Protein-Tyrosine-Phosphatase Inhibitors- Unmet Needs
Protein-Tyrosine-Phosphatase Inhibitors- Market Drivers and Barriers
Protein-Tyrosine-Phosphatase Inhibitors- Future Perspectives and Conclusion
Protein-Tyrosine-Phosphatase Inhibitors Analyst Views
Protein-Tyrosine-Phosphatase Inhibitors Key Companies
Appendix
List of Table
Table 1: Total Products for Protein-Tyrosine-Phosphatase Inhibitors
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Protein-Tyrosine-Phosphatase Inhibitors
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• REVOLUTION Medicines
• BridgeBio Pharma
• Genentech
• Jacobio Pharmaceuticals
• Aadi Bioscience
• Novartis
• Shanghai ETERN Biopharma
• HUYA Bioscience International
• Aerpio Pharmaceuticals
• HK inno.N
• Redx Pharma
• Navire Pharma
• Relay Therapeutics
• NeuBase Therapeutics
• Erasca
• Enterin
• Genaera Corporation
• Medesis Pharma
